Linking from ECCO's recent access to innovation position paper and its advocacy for refinement to the way in which value assessments are made about innovation, an ECCO-led project to investigate how value assessment methodologies might be applied to non-systemic oncology treatment has now commenced.
ESTRO President Professor Yolande Lievens leads the group. Other participants in the group include: Elizabeth De Vries, a medical oncologist involved in the development of the ESMO magnitude of benefit scale; Riccardo Audisio of ESSO and Ian Banks of the ECCO Patient Advisory Committee (ECCO PAC).
The project will be rolled out in two phases:
Page last modified:
- Phase 1 of the project will identify what methodologies for determining value of innovation in healthcare presently exist, critically evaluate these and make reflection as to their potential adapted application to non-systemic oncology treatment, by way of a published paper.
- Phase 2 of the project is intended to draw in the views of a wider range of stakeholders on the early conclusions formed in phase 1 with reporting on the prospects or not of a modified tool for establishing value in non-systemic oncology treatment innovations in time for the ECCO 2018 European Cancer Summit.